FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-23

Price

$14.42

-0.07%

Score6.2Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.7xvs 20d avg

Analysis

FOLD's price action is entirely dictated by its pending acquisition by BioMarin Pharmaceutical for $14.50 per share in cash, making it a pure merger arbitrage play. Recent shareholder approval cements the deal, perfectly explaining the ultra-low 2.0% realized volatility and the QUIET_STORM and STEADY_CLIMB signals as arbitrageurs pin the stock just below the buyout price. In the current CAUTION (GEOPOLITICAL) macro regime, FOLD's complete decoupling from VIX spikes and headline fears demonstrates absolute institutional absorption, offering a highly insulated risk profile.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable Thesis: FOLD is a definitive merger arbitrage play with a hard price ceiling at the $14.50 BioMarin cash buyout level.
Key Risk: Tail-risk of regulatory pushback or unexpected antitrust hurdles that could delay or derail the final closing.
What to Watch: Final regulatory clearances and the official closing timeline expected in Q2 2026.

← Back to 2026-03-23 View Full FOLD History →Yahoo Finance &nearr;